Exciting News from AllRock Bio on ROC-101 Development
ROC-101 demonstrates favorable pharmacokinetics for once-daily dosing.
The data supports its potential therapeutic efficacy, paving the way for a Phase 2 trial in pulmonary health slated to commence soon.
AllRock Bio, Inc., a pioneering clinical-stage biotechnology company, has unveiled encouraging Phase 1 data for its innovative oral pan-rho-associated protein kinase (ROCK) inhibitor, ROC-101, during the recent European Respiratory Society (ERS) Congress held in Amsterdam. This notable event took place from late September to early October.
The first-in-human study achieved its primary goals, indicating that ROC-101 is safe and well-tolerated. Further, it did not lead to hypotension and successfully engaged its target, reinforcing the need for ongoing evaluation in patients experiencing pulmonary arterial hypertension (PAH) and pulmonary hypertension connected with interstitial lung disease (ILD-PH).
Rho kinases are crucial players in various fibrotic disease mechanisms. Both ROCK1 and ROCK2 are noticeably active in multiple disorders, making their inhibition vital for tackling the complex inflammatory, proliferative, and fibrotic changes seen in conditions like PAH and ILD-PH. These conditions have disappointing five-year survival rates of around 57% and 38%, respectively.
Dr. William Marshall, CMO of AllRock, expressed confidence in ROC-101’s potential, stating, "The results from our Phase 1 trial confirm ROC-101 is a therapeutically promising compound. Our design focuses on targeting ROCK1 and ROCK2—both integral to the advancement of PAH and ILD-PH. We're dedicated to establishing a treatment that surpasses the outcomes provided by current therapies."
ROC-101’s unique action mechanism complements existing disease-modifying therapies within the pulmonary hypertension realm. AllRock has laid out plans for the Phase 2a ROCSTAR clinical trial to assess ROC-101’s effectiveness alongside standard care in patients with PAH and ILD-PH, expected to kick off by late 2025.
Catherine Pearce, CEO and co-founder of AllRock, emphasized the importance of this forward-thinking clinical trial design, stating, "With our structured approach, we aim to yield robust data, fulfilling the needs of both clinicians and patients while addressing significant unmet requirements to enhance patient outcomes."
The Phase 1 study was meticulously crafted as a randomized, double-blind trial, which included 92 healthy volunteers. Some key takeaways from the study include:
- Strong safety and tolerability: ROC-101 showcased excellent safety across all tested doses, with no hypotension recorded. The most common side effects noted were headache and constipation.
- Favorable pharmacokinetics (PK): PK data indicated that drug exposure increased proportionately with dosage. It was rapidly absorbed, supporting a once-daily dosing regimen.
- Effective target engagement: Pharmacodynamic (PD) data indicated a dose-dependent reduction in ROCK1 and ROCK2 activity.
- Superior exposure compared to peer inhibitors: Comparisons revealed ROC-101 achieved over 20 times the exposure relative to fasudil, a pan-ROCK inhibitor already in use for specific conditions.
Exploring ROC-101
ROC-101 stands out as an innovative oral pan-ROCK inhibitor currently in clinical trials for addressing PAH and ILD-PH. With its favorable pharmacokinetic profile supporting once-daily use, ROC-101 is specifically intended to inhibit both ROCK1 and ROCK2, which are pivotal in the inflammatory and fibrotic remodeling seen in serious cardiopulmonary diseases. Its action complements both approved and experimental therapies for pulmonary hypertension. The successful Phase 1 trial confirmed its safety and lack of hypotension incidence.
Understanding Pulmonary Arterial Hypertension (PAH)
PAH is a serious condition marked by elevated pressures in the pulmonary arteries that detrimentally affects the heart and lungs. The progressive narrowing of pulmonary vessels elevates arterial pressures, imposing extra demands on the right ventricle and straining the heart. Despite the availability of 16 approved drugs, including four classes of vasodilators, significant gaps remain in effective, disease-modifying treatments.
Insights into Interstitial Lung Disease-Associated Pulmonary Hypertension (ILD-PH)
ILD-PH represents a specific class of pulmonary hypertension that manifests with increasing pressures tied to interstitial lung disease, which includes various conditions impairing lung structure and function. Such diseases, like idiopathic pulmonary fibrosis, greatly impact breathing and are linked with high morbidity and mortality. Currently, limited treatment options exist for ILD-PH.
About AllRock Bio
AllRock Bio is devoted to pioneering transformative therapies for cardiopulmonary conditions. Their principal candidate, ROC-101, addresses critical unmet medical needs in the treatment landscape for PAH and hazardous fibrotic diseases. By leveraging a seasoned leadership team and a commitment to innovative solutions, AllRock aims to forge a new class of disease-modifying therapies for patients in need.
Frequently Asked Questions
What is ROC-101?
ROC-101 is a first-in-class oral pan-Rho kinase inhibitor designed to treat pulmonary arterial hypertension and ILD-PH.
What were the key findings of the Phase 1 trial for ROC-101?
The trial showed that ROC-101 is safe, well-tolerated, does not cause hypotension, and effectively engages its target.
When is the Phase 2 clinical trial expected to begin?
The Phase 2a ROCSTAR clinical trial is slated for late 2025.
How does ROC-101's safety profile compare to existing therapies?
In the Phase 1 trial, ROC-101 demonstrated strong safety and tolerability across all dose levels tested.
Why is AllRock Bio focused on pulmonary diseases?
AllRock Bio seeks to address significant unmet needs in the treatment of serious cardiopulmonary and fibrotic diseases with innovative therapies.
